+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis



A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis



Hepatology. 24(5): 1098-1103



The efficacy of colchicine combined with ursodeoxycholic acid (UDCA) and UDCA alone in the treatment of patients with nonadvanced primary biliary cirrhosis (PBC) was evaluated in a 2-year controlled study. Seventy-four patients with PBC who had been treated previously with UDCA (at least 8 months) but still had abnormal liver test results, especially elevated alkaline phosphatase activity, were randomized to be administered colchicine (1 mg/d, 5 days per week) (n = 37) or a placebo (n = 37). In addition, the patients were treated with UDCA (13-15 mg cntdot kg-1 cntdot day-1). The patients underwent clinical examination and liver tests every 6 months and upper endoscopy and liver biopsy at entry and at 2 years. Procollagen type III aminoterminal peptide (PIIINP), hyaluronic acid, and sulfobromophthalein (BSP) elimination kinetics were determined at entry and after 2 years. After 2 years of treatment, relative to UDCA, colchicine combined with UDCA did not significantly improve symptoms, laboratory findings (serum bilirubin level, alkaline phosphatase and alanine transaminase (ALT) activities, immunoglobulin (Ig) M level), serum markers of fibrosis, or histological features, except lobular inflammation. Colchicine did tend to slightly reduce the progression of esophageal varices; however, the difference was not significant. BSP elimination kinetics (45-minute retention percentage) was significantly improved when treated with colchicine. During the 2-year study, the only clinical complications were variceal bleeding in one patient administered colchicine and two administered the placebo. Two patients died from nonliver causes. One severe adverse effect (peripheral neuromyopathy) was observed in a colchicine- treated patient. In conclusion, this study suggests that colchicine appears to provide a slight advantage relative to UDCA alone in patients with nonadvanced PBC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008069253

Download citation: RISBibTeXText

PMID: 8903382

DOI: 10.1053/jhep.1996.v24.pm0008903382


Related references

A randomized trial comparing the combination ursodeoxycholic acid and colchicine to UDCA alone in primary biliary cirrhosis. Hepatology 20(4 PART 2): 151A, 1994

The Italian multi-centre randomized controlled trial of ursodeoxycholic acid vs ursodeoxycholic acid plus colchicine in symptomatic primary biliary cirrhosis. Hepatology 20(4 PART 2): 267A, 1994

The effects of colchicine and methotrexate are additive to ursodeoxycholic acid for patients with primary biliary cirrhosis who respond incompletely to ursodeoxycholic acid. Hepatology 26(4 PART 2): 438A, 1997

Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. Alimentary Pharmacology & Therapeutics 14(12): 1645-1652, 2000

A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Alimentary Pharmacology & Therapeutics 12(10): 965-971, 1998

Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: A double-blind, placebo-controlled trial on symptomatic patients. Alimentary Pharmacology & Therapeutics 15(9): 1427-1434, 2001

Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis. Journal of Gastroenterology & Hepatology 7(3): 277-282, 1992

A trial of ursodeoxycholic acid and colchicine in primary biliary cirrhosis. Hepatology 20(4 PART 2): 151A, 1994

A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group. Alimentary Pharmacology and Therapeutics 12(10): 965-971, 1998

The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. Journal of Hepatology 27(1): 143-149, 1997

Improvement of serum noncholesterol sterols may indicate retarded progression of primary biliary cirrhosis in a randomized placebo controlled two-year trial with colchicine and ursodeoxycholic acid. Gastroenterology 104(4 SUPPL ): A954, 1993

A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology. 108(5): 1470-1478, 1995

Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: A prospective randomized study. Journal of Hepatology 24(1): 88-94, 1996

A randomized controlled trial of ursodeoxycholic acid udca in primary biliary cirrhosis pbc. European Journal of Clinical Investigation 19(2 PART 2): A15, 1989

Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone. Journal of Hepatology 18(1): 9-14, 1993